Document Detail

Pharmacologic interactions of multidrug therapy for dyslipidemia.
MedLine Citation:
PMID:  23299643     Owner:  NLM     Status:  In-Data-Review    
Despite the best available medical therapy inclusive of statins, substantial residual risk remains for atherothrombotic cardiovascular disease. Non-statin lipid-lowering therapy may help address this critical unmet need through reduction of the levels of low-density lipoprotein and other atherogenic lipoproteins. In the past few years, several landmark trials have provided important information regarding the efficacy and safety of non-statin therapy for dyslipidemia and cardiovascular risk reduction.
Nidhi Mehta; Emil M Degoma
Related Documents :
23671433 - Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia...
15346663 - The human chorionic gonadotropin molecule from patients with trophoblastic diseases has...
8418763 - Factor vii assays.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  15     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  303     Citation Subset:  IM    
Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 9 Gates Building 3400 Spruce Street, Philadelphia, PA, 19103, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Advances in pharmacologic therapies for type 2 diabetes.
Next Document:  Imaging of vulnerable plaques using near-infrared spectroscopy for risk stratification of atheroscle...